As pointed out before, all ALS patients should be tested for RE in the C9Orf72 gene, given the extreme variability in familial occurrence and AAO, the relatively low cost of the test and the forthcoming of C9orf72-targeted therapeutic trials [47]. Here, C9orf72 is linked to amyotrophic lateral sclerosis.